Prognostic Value of Endothelin-1 Level in Diabetic Patients with Coronary Artery Disease

Mostafa Attia Eldegwi¹, *, Waleed Abdou Ibrahim², Ibrahim Shehata Elmadbouh³, Ahmed Abdullah Mostafa⁴, Abdullah Mostafa Kamal²

¹Cardiology Department, Shibin Elkom Teaching Hospital, General Organization of Teaching Hospitals and Institutes, Ministry of Health, Shibin Elkom, Egypt
²Cardiology Department, Faculty of Medicine, Minoufia University, Shibin Elkom, Egypt
³Biochemistry Department, Faculty of Medicine, Minoufia University, Shibin Elkom, Egypt
⁴Cardiology Department, Police Academic Hospital, Ministry of Interior, Cairo, Egypt

Email address: mostafa55degwi@gmail.com (M. A. Eldegwi), abdthallium2@gmail.com (A. M. Kamal)
*Corresponding author

To cite this article:
Mostafa Attia Eldegwi, Waleed Abdou Ibrahim, Ibrahim Shehata Elmadbouh, Ahmed Abdullah Mostafa, Abdullah Mostafa Kamal. Prognostic Value of Endothelin-1 Level in Diabetic Patients with Coronary Artery Disease. American Journal of Clinical and Experimental Medicine. Vol. 8, No. 2, 2020, pp. 20-25. doi: 10.11648/j.ajcem.20200802.13

Received: February 28, 2020; Accepted: March 13, 2020; Published: May 28, 2020

Abstract: Objective: The aim of this work is to study the prognostic value of the plasma level of the new marker, endothelin-1 (ET-1), in diabetic patients with coronary artery disease. Background: Endothelin 1 (ET-1) has been demonstrated to play a role in endothelial dysfunction and inflammation, both of which are actively involved in the pathophysiology of the onset and progression of coronary artery disease (CAD). Diabetes mellitus increases the risk of CAD and has unfavorable effects on the vascular endothelium, hence the importance of assessing this plasma marker and its relation to the severity of CAD in diabetic patients. Patients & method: This is a cross sectional study in which data was collected from January 2019 to December 2019 and was carried out on patients selected from catheterization laboratory, faculty of medicine, Minoufia university hospital, Egypt. A total of seventy patients, 35 diabetics (groupII, GI) and 35 non-diabetics (groupII, GII), with coronary artery lesions of not less than 50% in at least one main coronary artery plus twenty patients with normal coronaries as a control group (groupIII, GIII) were enrolled. The severity of coronary artery lesions were assessed by GINSINI score (GS) and the relationship between ET-1 level and GS was evaluated. Results: The ET-1 levels were significantly higher in GI with higher GS values of 34.29± 11.7 points and SYNTAX scores of 18.4±11.17 points, than in GII with lower GS values of 23.23±8.14 points and SYNTAX of scores 12.06±12.11 points (ET-1 was 187.93±146.61 ng/L in GI versus 76.30±91.83ng/L in GII, P value=0.001). ET-1 levels were significantly higher in GI than in GIII (187.93±146.61ng/L versus 26.16±7.32 ng/L, P value=0.001). ET-1 levels were significantly higher in GII than in GIII (76.30±91.83 ng/L versus 26.16±7.32 ng/L, P value=0.001). Conclusion: There is a positive correlation between DM and both ET-1 levels and the severity of coronary artery lesions, P value 0.001.

Keywords: Plasma Endothelin-1, Coronary Artery Disease, Risk Factors

1. Introduction

Coronary artery disease (CAD) is recognized as a health threat worldwide and remains a leading cause of both morbidity and mortality [1].

Hence, understanding its predictors would greatly aid in disease prevention and treatment, and the possible relationship between various plasma markers and CAD had intensively been investigated [2].

Among these markers, endothelin 1 (ET-1) has been demonstrated to play a role in endothelial dysfunction and inflammation [3], both of which are actively involved in the pathophysiology of the onset and progression of CAD, from the formation of acute coronary syndrome (ACS) and heart
failure following myocardial infarction [4].

Moreover, it has been reported that the baseline plasma ET-1 level can be used to predict the short- or long-term outcomes in patients with ACS and/or acute heart failure [5].

More importantly, little studies focusing on the diagnostic value of the plasma ET-1 level for discriminating the severity of CAD have been conducted.

Recently, big ET-1, the biological precursor of ET-1, with a longer half-life has been reported to be a more accurate indicator.

Therefore, in this study we tried to explain the usefulness of the plasma big ET-1 level in predicting the severity of CAD in diabetic patients.

2. Patients and Methods

2.1. Study Population

This is a cross sectional study in which data was collected from January 2019 to December 2019 from patients selected from cardiology department, faculty of medicine, Minoufia university hospital, Egypt. The current study included 90 patients who were divided, according to the presence or absence of diabetes mellitus (DM) and coronary artery disease (CAD), into three groups:

- Group I (GI): 35 Diabetic patients with CAD.
- Group II (GII): 35 Non-diabetic patients with CAD.
- Group III (GIII control group): 20 Non-diabetic patients with normal coronary angiography.

2.2. Design of the Study

Sampling: The study group was chosen by convenient sample technique.

Data collection:
- A case record form was used.
- A written informed consent was obtained from all subjects.

2.2.1. History and Laboratory Tests

All subjects were submitted to the following:
1. Full history taking.
2. Full clinical examination.
3. Surface 12-lead ECG using CONTEC ECG100G machine.
4. Fasting, postprandial blood sugar and HbA1C measurement.
5. Lipid profile.
6. Serum levels of endothelin-1 (ET-1) was measured before coronary angiography using a highly sensitive and specific commercial sandwich enzyme immunoassay and was correlated with scoring assessment of coronary arteries.

2.2.2. Echocardiography

It was done using VIVID S5 machine stressing on EF, RWMA and scoring of the 16 LV segments according to American society of echocardiography as follows: normokinesia (1 point): normal wall thickening and endocardial excursion, hypokinesia (2 points): reduced wall thickening and endocardial excursion, akinesia (3 points): absence of wall thickening and endocardial excursion, dyskinesia (4 points): systolic outward stretching or thinning.

Then the WMSI was calculated by dividing the total points over the number of LV wall segments, 16, where WMSI of 1 is normal, 1.5, 2, 2.5 being mild, moderate and severe hypokinesia respectively and finally 3 for akinesia [6].

2.2.3. Coronary Angiography

It was done using PHILIPS catheterization device, and Scoring of coronary artery lesions using SYNTAX and GINSINI scoring systems for each patient.

2.2.4. Statistical Analysis of the Collected Data [7]

Results were collected, tabulated and statistically analyzed by an IBM compatible personal computer with SPSS statistical package version 23 (SPSS Inc. Released 2015. IBM SPSS statistics for windows, version 23.0, Armonk, NY: IBM Corp.). Categorical data were expressed as number and percentage. Continuous data were expressed as mean and standard deviation. Suitable tests of significance were calculated. Comparison between groups was done using the Chi-square test or Fishers Exact test for categorical data and student t-test or ANOVA (F) test when suitable for Continuous data. The accepted level of significance in this work was 0.05.

3. Results

This study included 59 male patients (65.6%) and 31 female patients (34.4%) with 32-75 (mean: 58.21+8.46 and median 59) years of age. Analysis of anginal symptoms showed that 74 patients (82.2%) had chest pain and 16 patients (17.8%) had exertional dyspnea as shown in Table 1.

Patients were divided into three groups and were compared regarding sex, age, risk factors and their complaints as shown in Table 2.

Group I includes 35 diabetic patients of which 24 patients (68.6%) were males and 11 patients (31.4%) were females with 47-75 (mean: 61+6.27 and median age of 63) years of age. 8 patients (22.9%) had dyslipaeemia. 26 patients (74.3%) were complaining of exertional chest pain and 9 patients (25.7%) were complaining of exertional dyspnea.

Group II includes 35 patients of which 18 patients (51.4%) are males and 17 patients (48.6%) are females with 42-74 (mean: 59.03+8.8 and median age of 59) years of age. 28 patients (74.3%) had dyslipaeemia. 26 patients (74.3%) had HTN, 8 patients (22.9%) were smokers and 18 patients (51.4%) had dyslipaeemia. 28 patients (80%) were complaining of exertional chest pain and 7 patients (20%) were complaining of exertional dyspnea.

Group III includes 20 patients of which 15 patients (75%) are males and 5 patients (25%) are females with 32-70 (mean: 58.9+8.1 and median age of 57) years of age. 13 patients (65%) had HTN, 7 patients (35%) were smokers. These patients were complaining of chest pain.

In our study we did Comparison of ejection fraction (EF), laboratory investigations and scoring systems of CAD among the three groups as shown Table 3.
There was no significant difference regarding the (EF) between group I and group II (43.69±5.38% versus 45.29±5.09%, P=0.194) while there was a high significant difference between G1 and GIII regarding EF (43.69±5.38 versus 63.5±4.65, p<0.001) and between GII and GIII. There was a high significant difference between GII and GIII regarding EF (45.29±5.09% versus 63.5±4.65, p=0.001).

There was no significant difference regarding the WMSI between group I and group II (P=0.194) while there was a high significant difference between G1 and GIII regarding EF (p<0.001) and between GII and GIII (p<0.001) as shown in figure 1.

There was a positive correlation between the WMSI and the level of ET-1 and SYNTAX and GINSINI scores which were higher in GI and GII compared to GIII (p=0.001).

Importantly, the ET-1 levels were significantly higher in GI with high GS values of 34.29±11.7 points and SYNTAX scores of 18.4+11.17 points, than in GII with lower GS values of 23.23±8.14 points and SYNTAX of scores 12.06+12.11 points (187.93+146.61 ng/L in GI versus 76.30+91.83ng/L, P value=0.001).

ET-1 levels were significantly higher in GI than in GIII (187.93+146.61ng/L versus 26.16+7.32 ng/L, P value 0.001).

ET-1 levels were significantly higher in GI than in GII (76.30+91.83 ng/L versus 26.16+7.32 ng/L, P value 0.001).

ET-1 levels were significantly higher in GI than in GIII (76.30+91.83 ng/L versus 26.16+7.32 ng/L, P value=0.001).

This means that there is a positive correlation between DM and both the severity of coronary artery lesions and ET-1 levels.

There was a positive correlation between plasma levels of ET-1 and the number of coronary arteries affected (P value 0.001) as its levels were the highest among patients with multivessel CAD (ET-1 219.34±14.65ng/L) followed by LM lesions (172.87±17.2) then two vessel CAD (157.31±16.79) then CTO lesions (113.16±12.13) and at last one vessel CAD (69.28±7.77) as shown in Table 4 and figure 1.

The plasma ET-1 level indicated a strong discriminatory power for predicting a high GS, and the optimal cutoff value of the plasma ET-1 level for predicting a high GS was 48.36 ng/L, with a sensitivity of 77.1% and specificity of 80%. Higher levels of ET-1 were detected in diabetic patients with CAD, group I, compared to non-diabetic patients with CAD, group II as shown in Table 5.

Table 1. Demographics and complaints of studied groups.

| Variable | G1 | G2 | G3 |
|----------|----|----|----|
| Gender   |    |    |    |
| Male     | 24 | 18 | 15 |
| Female   | 11 | 17 | 25 |
| Age      |    |    |    |
| Mean±SD  | 59 | 31 | 32 |
| Range    |    |    |    |
| Median   | 68.6 | 51.4 | 48.6 |
|          | 68.6 | 51.4 | 48.6 |
|          | 68.6 | 51.4 | 48.6 |

*p standard deviation.

Table 2. Comparison of demographic data, risk factors and complaints of the studied groups.

| Variable | G1 | G2 | G3 | Test of significance | P value |
|----------|----|----|----|----------------------|---------|
| Gender   |    |    |    | χ²                   | 0.15    |
| Male     | 24 | 18 | 15 | 0.15                 | NS      |
| Female   | 11 | 17 | 25 | 3.73                 | NS      |

Figure 1. Comparison of wall motion scoring index (WMSI) among studied groups.
### Table 3. Comparison of investigations, EF%, WMSI, ET-1, coronary angiographic scoring among studied groups.

| Variable         | Group I No=35 | Group II No=35 | Group III No=20 | Test of significance | P value |
|------------------|---------------|----------------|-----------------|----------------------|---------|
| **LDL**          |               |                |                 |                      |         |
| Mean±SD          | 136.31±25.4   | 151.8±36.03    | 68.60±5.74      | F                    | <0.001  |
| Range            | 110-260       | 100-250        | 55-77           |                      |         |
| Median           | 128           | 140            | 69              |                      |         |
| Post Hoc HbA1C   | P1=0.022 P2=0.001 P3=0.001 | P1=0.001 P2=0.001 P3=0.001 | | | |
| Mean±SD          | 12.19±1.48    | 4.72±0.24      | 2.42            | t                    | <0.001  |
| Range            | 9-15          | 4.30-5.20      |                 |                      |         |
| Median           | 12            | 4.7            |                 |                      |         |
| ET-1 (ng/L)      |               |                |                 |                      |         |
| Mean±SD          | 187.93±146.61 | 76.30±91.83    | 26.16±7.32      | K                    | <0.001  |
| Range            | 29-428        | 26-385         | 15-37           |                      |         |
| Median           | 141           | 40-64          | 24.26           |                      |         |
| Post Hoc EF%     | P1=0.001 P2=0.001 P3=0.001 | P1=0.001 P2=0.001 P3=0.001 | | | |
| Mean±SD          | 43.69±5.38    | 45.29±5.90     | 63.5±4.65       | F                    | <0.001  |
| Range            | 30-52         | 30-53          | 56-72           |                      |         |
| Median           | 44            | 46             | 62.5            |                      |         |
| Post Hoc WMSI    | P1=0.194 P2=0.001 P3=0.001 | P1=0.194 P2=0.001 P3=0.001 | | | |
| Mean±SD          | 2.7±0.38      | 2.6±0.42       | 1               | F                    | <0.001  |
| Range            | 1.5-3         | 1.5-3          |                 |                      |         |
| Median           | 2.5           | 2.5            |                 |                      |         |
| Post Hoc SYNTAX score | P1=0.194 P2=0.001 P3=0.001 | P1=0.194 P2=0.001 P3=0.001 | | | |
| Mean±SD          | 18.40±11.17   | 12.06±12.11    |                 |                      | 2.42    |
| Rang             | 2-38          | 2-38           |                 |                      |         |
| Median           | 20            | 6              |                 |                      |         |
| GINSINI score    |               |                |                 |                      |         |
| Mean±SD          | 34.29±11.7    | 23.23±8.14     |                 |                      | 4.44    |
| Rang             | 20-60         | 12-40          |                 |                      |         |
| Median           | 32            | 20             |                 |                      |         |

F=Anova test t=Student’s t test U=Mann-whiteny test K=Kruskual walls test HS=High significant WMSI=wall motion scoring index EF=ejection fraction.
Group I=Diabetic patients with CAD.
Group II=Non-Diabetic patients with CAD.
Group III=Control.
P1=Group I versus Group II.
P2=Group I versus Group III.
P3=Group II versus Group III.
### Table 4. Relationship between coronary artery lesion and ET-1.

| Coronary artery lesion site | ET-1 Mean±SD | Test of significance | P value |
|----------------------------|--------------|----------------------|--------|
| 1 vessel                   | 69.28±7.77   | K                    | 0.001  |
| LM                         | 172.87±17.2  | 13.32                |        |
| 2 vessels                  | 157.31±16.79 | S                    |        |
| MVD                        | 219.34±14.65 |                      |        |
| CTO                        | 113.16±12.13 |                      |        |
| Lesion severity            |              |                      |        |
| Moderate                   | 82.19±5.59   |                      | 0.046  |
| Severe                     | 138.56±14.54 |                      |        |

ET-1=Endothelin-1 U=Mann-whitney test K=Kruskual wails test S=significant.
LM=left main artery CTO=chronic total occlusion.

### Table 5. Validity of Endothelin-1 (ET-1) as a predictor of the severity of coronary artery disease (CAD) in diabetic patients.

| ET-1    | AUC | P value | Cutoff point | Sensitivity | Specificity | PPV | NPV |
|---------|-----|---------|--------------|-------------|-------------|-----|-----|
| 0.84    | 0.001 | ≥48.36   | 77.10%       | 80%         | 71%         | 86% |

AUC=area under the curve PPV=positive predictive value NPV=negative predictive value.

### 4. Discussion

The endothelium plays an integral role in the regulation of vascular tone, platelet activity, leukocyte adhesion, and thrombosis and is intimately involved in the development of atherosclerosis. Endothelial dysfunction has been observed in patients with established coronary artery disease or coronary risk factors, both in the coronary and peripheral vasculature [8, 9]. Coronary endothelial dysfunction in epicardial or resistance vessels is typically accompanied by myocardial perfusion defects suggestive of ischemia. In patients with dysfunctional endothelium, the loss of flow-mediated and catecholamine-stimulated nitric oxide (NO) release and increased production of endothelin-1 permits unopposed constriction to catecholamines. Thus, the loss of nitric oxide (NO) and increased levels of endothelin-1 may contribute to impaired dilation or constriction of epicardial and resistance vessels.

Endothelial dysfunction and reduced NO with increased levels of endothelin-1 in particular, may play an important role in destabilizing atherosclerotic plaques as well. Endothelial dysfunction, increased production of endothelin-1 and deficiency of NO exacerbates myocardial ischemia in patients with stable angina or acute ischemic syndromes. In addition, endothelial dysfunction may predispose to a transition from stable to unstable ischemic syndromes [10, 11]. The aim of this work was to study the prognostic value of a new marker, endothelin-1 (ET-1), level in diabetic patients with coronary artery disease and to determine its relation to the clinical presentation, cardiovascular risk factors and the extent, severity and angiographic lesion morphology of coronary atherosclerosis. Seventy patients with coronary artery disease were included, 35 with diabetes mellitus (DM) (group 1) and 35 without DM (group 2), versus twenty patients with normal coronary arteries as a control group (group 3). This study showed that plasma endothelin-1 levels are significantly elevated in patients with DM and CAD as compared to those without DM [12, 13].

There was a significant association between plasma endothelin-1 levels and the number of arteries affected by atheroma in humans. In the present study, the demonstration of significantly higher levels of plasma endothelin-1 in patients with DM and CAD than in normal persons (187.93±146.61 versus 26.16±7.32 ng/L, p=0.001) suggests a role for this peptide in the pathophysiology of coronary atheroma [14].

The trend towards an association between elevated plasma endothelin levels and severity of coronary artery disease observed in this study may, therefore, reflect the degree of associated endothelial dysfunction [15]. The present study demonstrates a positive correlation between the plasma endothelin-1 level and the severity & number of diseased coronary segments.

In our study we examined the relation between plasma endothelin-1 and the angiographic equivalent of diabetic patients with CAD. The plasma endothelin-1 level was significantly elevated in patients with DM and CAD when compared with healthy control subjects (187.93±146.61 versus 26.16±7.32 ng/L, p=0.001) and patients without DM but with CAD (76.30±91.83 ng/L, p=0.001). This observation indicates that endothelin-1 has a good predictive value for the severity of CAD in diabetic patient.

### 5. Conclusion

1. Plasma endothelin-1 levels were significantly higher in diabetic patients with CAD when compared with normal persons.
2. Plasma endothelin-1 levels were significantly higher in non-diabetic patients with CAD when compared with normal persons.
3. Plasma endothelin-1 levels were significantly higher in diabetic patients with CAD when compared with non-diabetic patients with CAD.
4. A positive correlation between the plasma endothelin-1 level and the severity of coronary artery disease as assessed by SYNTAX and Ginsi scores had been identified.
6. Recommendations

Plasma endothelin-1 may be used as a surrogate marker for the severity of coronary artery disease in diabetic patients with evidence of ischaemic heart disease (IHD).

References

[1] Roger VL: Epidemiology of myocardial infarction. Med Clin North Am, 2007; 91: 537-552.
[2] Hong LF, Li XL, Luo SH: Association of fibrinogen with severity of stable coronary artery disease in patients with type 2 diabetes mellitus. Dis Markers, 2014; 485687.
[3] Kolettis TM, Barton M, Langleben D: Endothelin in coronary artery disease and myocardial infarction. Cardiol. Rev., 2013; 21: 249-256.
[4] Khimji AK, Rockey DC: Review: Endothelin-Biology and disease. Cell Signal, 2010; 22: 1615-1625.
[5] Freixa X, Hears M, Ortiz JT: Usefulness of endothelin-1 assessment in acute myocardial infarction. Revista Espanola de Cardiologia (English Edition), 2011; 64: 105-110.
[6] Lebeau R, Serri K, Lorenzo MD, Sauvé C, Le VIH, Soulières V, El-Rayes M, Pagé M, Zaitani C, Garot J, Poulin F. Assessment of LVEF using a new 16-segment wall motion score in echocardiography. (2018) Echo research and practice. 5 (2): 63-69. doi: 10.1530/ERP-18-0006 - Pubmed.
[7] Chap T, Le, Lynn. E. Eberly: Introduction to biostatistics second edition (2016).
[8] Wesson D, Simoni J, Green DF. Reduced extracellular pH increases endothelin-1 secretion by human renal microvascular endothelial cells. J Clin Invest 1998; 101: 578-83.
[9] Zeiher AM, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoactivity of the culprit lesion in unstable angina. Circulation 2012; 91: 941-7.
[10] Vanhoutte PM. How to assess endothelial function in human blood vessels. J Hypertens 1999; 17: 1047-1058.
[11] Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans: Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 2009; 83: 391-401.
[12] Lin CL, Dumont AS, Wu SC, Wang CJ, Howng SL, Huang YF, et al. 17beta-estradiol inhibits endothelin-1 production and attenuates cerebral vasospasm after experimental subarachnoid hemorrhage. Exp Biol Med (Maywood) 2006; 231: 1054–7.
[13] Novo G, Sansone A, Rizzo M, Guarneri FP, Pernice C, Novo S. High plasma levels of endothelin-1 enhance the predictive value of preclinical atherosclerosis for future cerebrovascular and cardiovascular events: a 20-year prospective study. J Cardiovasc Med (Hagerstown) 2014; 15: 696–701. doi: 10.2459/JCM.
[14] Hellgren MI, Daka B, Jansson PA, Lindblad U, Larsson CA. Insulin resistance predicts early cardiovascular morbidity in men without diabetes mellitus, with effect modification by physical activity. Eur J Prev Cardiol. 2015; 22 (7): 940–9. doi: 10.1177/2047487314537917.
[15] Ding D, Starke RM, Dumont AS, Owens GK, Hasan DM, Chaluhi N, et al. Therapeutic implications of estrogen for cerebral vasospasm and delayed cerebral ischemia induced by aneurysmal subarachnoid hemorrhage. Biomed Res Int. 2014; 2014: 727428.